Marker 01

“Once a scientist, forever a scientist,” says Legend Biotech CEO Ying Huang as he joins Bloomberg Intelligence analyst Sam Fazeli to share his unconventional journey from the lab bench to Wall Street and back to biotech leadership. Dr. Huang explains how a dream led him from equity research to developing one of the most important CAR-T therapies for multiple myeloma. They explore the science behind BCMA targeting, lessons from the pivotal Johnson & Johnson partnership as well as the company’s ambitions in allogeneic and in-vivo therapies.

&ldquo;Once a scientist, forever a scientist,&rdquo; says Legend Biotech CEO Ying Huang as he joins Bloomberg Intelligence analyst Sam Fazeli to share his unconventional journey from the lab bench to Wall Street and back to biotech leadership. Dr. Huang explains how a dream led him from equity research to developing one of the most important CAR-T therapies for multiple myeloma. They explore the science behind BCMA targeting, lessons from the pivotal Johnson &amp; Johnson partnership as well as the company&rsquo;s ambitions in allogeneic and in-vivo therapies.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Legend Biotech's Race to Make Cell Therapy Mainstream

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e1001f9a-ce54-4cd8-a4fb-b3520136a9bc/transcript

Vanguards of Health Care: Penumbra Expands CAVT Awareness “With pulmonary embolism, just like with stroke and some other things, where there’s an acute moment usually happening — the patient’s not doing well, decompressing on the table — time matters a lot. And because of the STORM-PE trial, we have the data on what that device time is in a pretty rigorous randomized study. And it just doesn’t compare to anything else out there. It’s dramatically less”, Penumbra CEO Adam Elsesser explains to Bloomberg Intelligence.


In this Vanguards of Health Care episode, Elsesser sits down with BI medical technology analyst Matt Henriksson for an in-depth interview on Penumbra and how computer-assisted vacuum thrombectomy (CAVT) technology continues to improve, cutting the time to remove the clot while limiting blood loss. He also dives deep into the clinical results of the STORM-PE randomized clinical study, highlighting how CAVT demonstrated superiority over the standard of care to treat pulmonary-embolism patients, and its partnership with the PERT Consortium to drive public awareness of the need to treat this devastating disease.

Vanguards of Health Care: Penumbra Expands CAVT Awareness &ldquo;With pulmonary embolism, just like with stroke and some other things, where there&rsquo;s an acute moment usually happening &mdash; the patient&rsquo;s not doing well, decompressing on the table &mdash; time matters a lot. And because of the STORM-PE trial, we have the data on what that device time is in a pretty rigorous randomized study. And it just doesn&rsquo;t compare to anything else out there. It&rsquo;s dramatically less&rdquo;, Penumbra CEO Adam Elsesser explains to Bloomberg Intelligence.
 In this Vanguards of Health Care episode, Elsesser sits down with BI medical technology analyst Matt Henriksson for an in-depth interview on Penumbra and how computer-assisted vacuum thrombectomy (CAVT) technology continues to improve, cutting the time to remove the clot while limiting blood loss. He also dives deep into the clinical results of the STORM-PE randomized clinical study, highlighting how CAVT demonstrated superiority over the standard of care to treat pulmonary-embolism patients, and its partnership with the PERT Consortium to drive public awareness of the need to treat this devastating disease.

Penumbra Builds Clinical Support Showing Computer Assistance Can Better Address Clot

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d9c7abb2-8d75-424a-b5a2-b3b6013396f0/transcript

“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.

&ldquo;Drug development has become slower and more expensive despite all the new technology,&rdquo; says Eric Hughes, executive vice president of Global R&amp;D and chief medical officer of Teva Pharmaceutical. &ldquo;That&rsquo;s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we&rsquo;re in a unique position where we can stay really hyper-focused on what we&rsquo;re doing. I&rsquo;m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they&rsquo;re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva&rsquo;s doing right.&rdquo; In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&amp;D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.

Teva a Generic Giant With Biotech Bite

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c2b717d6-2e03-48ae-871b-b3b100c8e6b4/transcript

“AI agents are at the knee of the curve in terms of where things are headed,” says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis’s thesis-driven approach to founding AI-native health-care companies. He details how its 14-system consortium sources problems directly from operators, why automation is the biggest near-term value driver and how ventures like Ascertain have emerged from that model. Beadle also discusses the evolving venture market, the rise of agentic AI and why his personal experiences, shaped by his mother’s medical journey, fuel his mission to make the system more accessible and equitable.

&ldquo;AI agents are at the knee of the curve in terms of where things are headed,&rdquo; says John Beadle, Aegis Ventures co-founder and managing partner. In this episode of the Vanguards of Health Care podcast, Beadle joins Bloomberg Intelligence analyst Jonathan Palmer to unpack Aegis&rsquo;s thesis-driven approach to founding AI-native health-care companies. He details how its 14-system consortium sources problems directly from operators, why automation is the biggest near-term value driver and how ventures like Ascertain have emerged from that model. Beadle also discusses the evolving venture market, the rise of agentic AI and why his personal experiences, shaped by his mother&rsquo;s medical journey, fuel his mission to make the system more accessible and equitable.

Aegis Ventures’ Blueprint for Building AI-Native Companies

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/a3e610d6-87f2-4a01-afc5-b3a900450404/transcript

Legend Biotech's Race to Make Cell Therapy Mainstream

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips